Medarex MEDX
-
New Morningstar Analyst Report - ViroPharma, Inc.
… the firm, we are encouraged by Milano's degree of experience at ViroPharma, and we like that that ViroPharma named former Medarex CEO Howard Pien as lead independent director. Furthermore, we think executives are compensated reasonably for such a profitable …
-
Celldex Therapeutics: A Potential Triple With Data On The Way
… tribulations ahead, but risk-tolerant investors may want to consider these shares before trial data and partnerships move the stock from these levels. An Unconventional History Celldex was once part of Medarex (which is now Complete Story »
-
Time to Sell Bristol-Myers Squibb
… The transformation from an old-line drug company to focused leader in biotechnology was largely completed in 2009 with the Medarex acquisition. This piece of the puzzle provided a fast-track platform to the leading edge of the biotechnology business …
-
Japan After The Quake: Assessing short- and medium-term effects
Medarex is a speculative biotech investment.
-
Bristol to Acquire ZymoGenetics
… reassured by Bristol's recent acquisition success, including backing away from an ImClone bidding war and proceeding to acquire Medarex , which netted an underappreciated melanoma drug candidate that posted blockbuster-worthy data this summer. As Bristol approaches …
-
Our Top Biotech Acquisition Picks for 2010
… collaborative fit with potential partners , profit - boosting power , and financial health . Investors who purchased shares of Medarex on the day our Mergers & Acquisitions : Outlook for 2009 report was published would have pocketed over a 200 % gain after Bristol …
-
New Morningstar Analyst Report - ViroPharma, Inc.
… usually disapprove of a lack of separation between the chief executive and chairman, we like that ViroPharma named Medarex MEDX CEO Howard Pien as lead independent director, and the remaining board members appear independent. Furthermore, we …
-
An Improving Merger Environment?
… 2 billion ( IBM's purchase of SPSS ) . In healthcare , two deals at the top of the list - - Bristol - Meyers'bid for Medarex and Dianippon's ( Japan ) bid for Sepracor - - were both valued in excess of $ 2 billion . The other 5 transactions in the …
-
POGRX PRIMECAP Odyssey Growth Fund Analysis, Report, Research, 5 Star Rating – Morningstar
… asset base makes it easier for the managers to move in and out of stocks, such as recent top-10 holdings Conceptus CPTS and Medarex , neither of which was in Capital Opportunity as of July 31, 2009. This fund has been a stellar performer in its short life …
-
Bristol to Buy Medarex
Medarex MEDX has announced that Bristol-Myers Squibb BMY will ..... and we are raising our fair value estimate for Medarex to match this $16 per share offer--a 90% premium to Medarex 's previous closing price. Bristol and Medarex …